Morgan Lewis

FDA & Healthcare Publications of Interest

For More Information

Read the Brochure

Read the FDA and Healthcare Practice brochure.

Read the Brochure

FDA Food Safety Modernization Act

Resources


Related Events

06/06/12-06/08/12 ABA’s Civil False Claims Act and Qui Tam Enforcement 2012
Katie McDermott, presenter, "Investigation of a False Claims Act Case"
06/06/12-06/07/12 2012 Health Law Institute in Minneapolis
Arianne Callender, speaker, "Fraud and Abuse Update"
06/09/12-06/12/12 The Business of Medicine 2012 San Diego Summit
Kathleen McDermott, presenter, "Shining a Light on the Sunshine Act: What You Need To Know"
View all events

Related Publications

05/22/12 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges, presented at the AHLA/FDLI's Intersecting Worlds of Drug, Device, Biologics and Health Law
05/03/12 HHS Plugs Payment Suspensions as Key Tool in Latest Takedown
The Medicare Fraud Strike Force's use of a pivotal ACA regulation to suspend payments during criminal investigations signals a turning point in its prosecution strategy.
05/02/12 Update on the Biosimilars Competition and Innovation Act: Overview and Life Cycle Planning for Biosimilars, presented at the BioNJ Diamond Circle Board of Trustees Meeting
(pdf)
View all publications

Related News

05/04/12 Regulatory Policy: CBER Importance Boosted With Attention To Biologic Drugs, Biosimilars, Speakers Say
Life Sciences and Healthcare partner Stephen Paul Mahinka is quoted.
04/05/12 Biosimilars Naming and Labeling: An FDLI Dialogue, Update Magazine
Life Sciences and Healthcare partner Stephen Paul Mahinka is quoted.
02/29/12 Morgan Lewis Partner Appointed to California Office of Privacy Protection Advisory Group
Morgan Lewis today announces that partner Reece Hirsch has be appointed to the California Office of Privacy Protection Advisory Group.
View all news

Fast Facts

PLCCross-border Quarterly 2012 Life Sciences Legal Market Review

  • Industry Super League - Ranked 14th among law firms worldwide
  • Regulatory Super League - Ranked 8th among law firms worldwide

PLCCross-border Life Sciences Handbook 2007/2008

  • U.S. - Recognized for commercial/ partnering, competition/ antitrust, corporate, government law enforcement/ investigations, regulatory, regulatory/ medical devices, and patent counseling
  • England - Recognized for regulatory
  • Japan - Recognized for corporate/commercial

Chambers USA 2012: Washington, D.C. for healthcare/ pharmaceutical/medical products regulatory – Band 3

UK Legal 500 2007/2008: London: Pharmaceuticals and Biotechnology

New Resource

New Resource: Health Industry Transparency Compliance Resource Center
341 Publications Found
page 2 of 19
03/09/12 Pharmacies and Suppliers Beware: It Is Not Just the Pill Mills They Are After

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
Kathleen Sanzo, Lee Rosebush, Michele Buenafe

DEA's recent position against a national pharmacy chain and a wholesale distributor expands the proactive monitoring and auditing requirements for pharmacies and wholesale distributors to include site visits and possibly medical necessity reviews.

February 2012 Co-author, Compliance Certifications and the Era of Accountability—A Forecast to Debate, Journal of Health & Life Sciences Law, Vol. 5, p. 158

Outside Publication | Article
Kathleen McDermott, Arianne Callender

02/09/12 FDA Issues Three Draft Guidances for Biosimilars

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
Stephen Mahinka, Phoebe Mounts, Alexis Miller, Kathleen Sanzo

Initial guidance provides insights on regulatory pathway for biosimilars, but does not address many critical issues.

02/06/12 CMS Proposes Major Changes to AMP Rule

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
Andrew Ruskin, Donna Lee Yesner, Stephen Ruscus

The Proposed Rule provides provisions that will significantly impact pharmaceutical manufacturers' rebate liability, price reporting calculations, and possibly their operations.

01/26/12 Transparency Compliance Webinar

Presentation | Webinar
Rebecca Osowski, Kathleen McDermott, Jonathan Havens

Morgan Lewis hosted a webinar focusing on the Centers for Medicare and Medicaid Services' (CMS) long-awaited proposed rule, "Transparency Reports and Reporting of Physician Ownership or Investment Interests." This webinar pr... more

01/25/12 2011 American Health Lawyer’s Association Annual Meeting

Presentation | Speech
Kathleen McDermott

Morgan Lewis's Kathleen McDermott presented "The Era of Individual Accountability-Is A Liability Hailstorm On The Way?" at the 2011 American Health Lawyer's Association Annual Meeting. Ms. McDe... more

01/11/12 FDA Gets (Un)Social

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
Kathleen Sanzo, Alexis Miller

FDA draft guidance on responding to requests for off-label information foreshadows restrictive policies on use of social media.

01/04/12 Physician-Vendor Relationships Under Heightened Scrutiny: Avoiding or Minimizing Liability Under False Claims, Stark, and Anti-Kickback Laws (a Strafford webinar)

Presentation | Webinar
Arianne Callender

Federal regulators and prosecutors are aggressively pursuing allegations of improper financial relationships between physicians and vendors. Areas of concern include the use of free samples, "sham" consulting and advisory payment... more

2011 Co-author, Prescription, Drug Promotions and Marketing, FDLI’s Food and Drug Law Regulation 2011, 2nd edition

Outside Publication | Article
Kathleen Sanzo, Stephen Mahinka

12/21/11 CMS Issues Transparency Reporting Proposed Rule

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
Rebecca Osowski, Kathleen McDermott, Jonathan Havens, Michele Buenafe

The Centers for Medicare and Medicaid Services' proposed rule, which will implement Section 6002 of the Patient Protection and Affordable Care Act, clarifies several definitions, provides further information on reporting requirements, and offers guidance on submitting required information.

12/05/11 Comparative Effectiveness Research: Impact on Pharmaceutical Pricing and Marketing, presented at the QI Productions Conference on Integrating Comparative Effectiveness Research, Philadelphia

Presentation | Speech
Stephen Mahinka

Topics presented include: Structural Changes in Pharmaceutical Industry Stimulating Focus on Comparative Effectiveness Research Potential Changes by Healthcare Reform Law Affecting Demand Levels and Prices/Payments ... more

12/02/11 Spotlight On Physician Owned Distributors: Stay Tuned For Agency Guidance, Health Lawyers Weekly

Outside Publication | Article
Arianne Callender, Howard Young

Agencies' recent responses to Senate call for action on physician-owned distributors offer few details on policies. Stakeholders must await CMS rulemaking and OIG study for possible answers. more

12/01/11 FTC/DOJ Final Policy Statement on Accountable Care Organizations: Important Antitrust Issues Remain Unanswered, BNA's Health Law Reporter

Outside Publication | Article
Stephen Mahinka, J. Everett, Jr., David Brenneman, Albert Shay

The Federal Trade Commission and the Department of Justice ("agencies") issued their final Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program ("... more

12/01/11 Government Program Integrity Enforcement and Child Behavioral Provider Focus Areas, presented at the National Association for Children’s Behavioral Health 2011 Technical Meeting, Orlando, FL

Presentation | Speech
Howard Young

2011 Seminal Fraud, Program Integrity and Transparency Provisions Complement the PPACA Reform Provisions (Chapter 5, co-author), Health Care Rulemaking Guide, Administrative Rules Implementing New Healthcare Laws (2011-2012 edition, West Publication)

Outside Publication | Chapter
Kathleen McDermott

11/16/11 Avoiding Anti-Kickback Challenges Related to Pricing and Contracting, presented at the 8th National Rx Drug Pricing Boot Camp, New York

Presentation | Speech
Andrew Ruskin

Topics presented include: Types of PAPs PAP Features Legal Concerns Price Reporting OIG PAP Guidance PAP Decision Points more

11/03/11 Implementing a CIA: Challenges and Lessons Learned, presented at the 12th Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum, Washington, D.C.

Presentation | Speech
Scott Memmott

10/31/11 FTC/DOJ Final Policy on Accountable Care Organizations: Important Antitrust Issues Remain Uncertain for Healthcare Collaborations

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
Stephen Mahinka, J. Everett, Jr., David Brenneman, Albert Shay

The Federal Trade Commission (FTC) and Department of Justice (DOJ) (together, the Agencies) issued their final "Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Sha... more

October 2011 Where Will Biosimilars Fit in Federal Drug Pricing Programs?, BNA's Pharmaceutical Law & Industry Report

Outside Publication | Article
Donna Lee Yesner

10/06/11 Physician-Owned Distributors and Agency Guidance: Still Waiting

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
Arianne Callender, Howard Young

Agencies' recent responses to Senate call for action on physician-owned distributors offer few details on policies. Stakeholders must await CMS rulemaking and OIG study for possible answers.

09/28/11 Don't Shoot the Messenger—Effective Compliance Strategies in View of Enhanced Whistleblower Incentives and Protections, Plus a Summary of Select Recent Enforcement Actions (a Blue Cross Blue Shield Association webinar)

Presentation | Webinar
Scott Memmott

09/28/11 Medical Necessity of Cardiac Implants: The New Enforcement Priority (a West Legal Education webinar)

Presentation | Webinar
Scott Memmott, Albert Shay

09/23/11 The Biosimilars Competition and Innovation Act: Overview and Life Cycle Planning for Biosimilars, presented at American Conference Institute’s FDA Boot Camp, Boston

Presentation | Speech
Stephen Mahinka

08/09/11 FDA Issues Draft Guidance on 510(k) Device Modifications: New Emphasis on Potential Impact of Modifications

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
Phoebe Mounts, M. Elizabeth Bierman, Michele Buenafe

On July 27, the Food and Drug Administration (FDA) issued a draft guidance titled "510(k) Device Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device."[1] Once ... more

07/28/11 New FDA Draft Guidance on Mobile Medical Apps Provides Some Clarity, But Raises Many More Questions

LawFlash/Client Alert | Life Sciences and Healthcare LawFlash
M. Elizabeth Bierman, Michele Buenafe

On July 19, the Food and Drug Administration (FDA) issued a new draft guidance document, titled Mobile Medical Applications , describing FDA's position on the regulation of mobile applications, i.e., software applications inten... more

page 2 of 19